In WM, four elongases (ELOVL1 (Kruskal-Wallis p=0.0008, post-hoc Dunn’s test ADIII-IV vs MA p=0.001, ADV-VI vs MA p=0.0028), ELOVL4 (Kruskal-Wallis p=0.001, post-hoc Dunn’s test ADV-VI vs MA p=0.0026), ELOVL6 (post-hoc Dunn’s test ADIII-IV vs MA p=0.027, ADV-VI vs MA p=0.018) and ELOVL7 (Kruskal-Wallis p=0.003, post-hoc Dunn’s test ADIII-IV vs MA p=0.02, ADV-VI vs MA p=0.0009)) decreased its expression in AD progression and whereas FADS1 increases (post-hoc Dunn’s test ADV-VI vs MA p=0.0067). This evidence concerns the gene ELOVL6 and Alzheimer disease.